Desang diabetes magazine diabetes news

NEWS

J&J CLOSES LIFESCAN SALE

Johnson & Johnson (J&J) has closed

the $2.1billion sale of its LifeScan blood

glucose monitoring subsidiary - which

includes the OneTouch blood test meter

brand - to private equity player Platinum

Equity. The sale is part of the New Jerseybased healthcare

conglomerate's move to

get out of the device end of the diabetes

healthcare arena, according to a report by

Drug Delivery Business.

Early last year J&J announced a

strategic review of the LifeScan, Animas

and Calibra Medical diabetes businesses,

later closing down the Animas insulin

pump subsidiary globally. In July CeQur

acquired Calibra Medical's insulin patchpump from

J&J, the same month the

company agreed the sale of the Lifescan

brand to Platinum Equity. In terms of what

this all means for people using LifeScan's

OneTouch products in the UK, absolutely

nothing changes. The LifeScan brand -

which has been around for 35 years - is

now a stand-alone company invested

in by Platinum Equity, which owns the

company but does not manage it. All

systems regarding blood test meter

supplies and company contact numbers

are set to remain the same for the

foreseeable future.

According to a statement, LifeScan

remains dedicated to servicing its patients

and their care teams. Its OneTouch brand

of blood glucose meters is well used

and liked globally. J&J plans to continue

to offer bariatric surgery products and

drugs like Invokana and Invokamet in the

diabetes sector.

www.myonetouch.co.uk

In a report by Sarah Faulkner for

Drug Delivery Business, Insulet has

announced that its Omnipod insulin

management system can be used with

Novo Nordisk's Fiasp. This insulin enters

the user's bloodstream two times faster

than NovoRapid and is designed to

match that of a non-diabetic's response

to a meal. Insulet has a team of more than

100 employees to take care of distributing

and selling its Omnipod system in Europe.

DJ Cass, GM of Insulet's Europe unit,

says, "The addition of Fiasp for use with

the Omnipod provides another option for

both patients and prescribers to support

their diabetes management needs."

www.omnipodeurope.com

FIASP FOR USE

IN OMNIPOD

Privately-held Dance Biopharm has

raised $24.5m in a private equity round to

help fund the development of its inhaled

insulin product. SternAegis Ventures was

the exclusive placement agent for the

offering. Molex Ventures, an electronics

company working with Dance to develop

a connected insulin delivery device,

contributed to the round. The Dance

501 device stores a liquid formulation of

recombinant human insulin in a dispenser

with a hand-held electronic inhaler. The

device uses vibrating mesh to produce

particles of liquid insulin in a soft mist.

Dance Biopharm chairman John

Patton commented, "This additional

capital is important as we continue to

prepare for more clinical trials for Dance

501 (our inhaled insulin product candidate

for diabetes), and we are delighted to

have SternAegis Ventures and Molex

enabling this new financing. The industry

is seeing a 9% global growth in new

diabetic patients each year,"

Lily Yeung, VP of Molex Ventures

added. "Dance Biopharm has taken the

complexity out of insulin delivery with an

innovative and much needed solution

designed to address the specific needs

of this growing market while supporting

device compliance and adherence. This

exciting technology and unique patient

care approach aligns well with our Molex

Ventures investment strategy."

INHALED INSULIN DEVICE

GETS FUNDING

WRIGHT STUFF

The winners of the Eat Wright book

giveaway in the July/August issue

were Jean McLean, Bill Bogmore and

Hilary Dann. With thanks to Leonie

Wright for donating the cookbooks.

NEED TO KNOW: Ketones & Sick Day Rules, p.

Index

  1. Desang diabetes magazine diabetes information
  2. Diabetes UK careline
  3. Desang diabetes magazine diabetes information, Sue Marshall
  4. Desang diabetes magazine diabetes news
  5. Desang diabetes magazine diabetes news
  6. Desang diabetes magazine diabetes news
  7. Dexcom CGM, continuous glucose monitoring
  8. Desang diabetes magazine diabetes news
  9. Ascensia Contour Next One Diabetes blood test meters
  10. Page 0010
  11. Senseonics Eversense implantable CGM, Roche Diabetes Care, Accu-Chek
  12. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  13. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  14. Abbott Freestyle Libre, Flash Glucose Monitoring, blood testing without lancets
  15. OurPath programme, Roche Diabetes Care
  16. diabetes and ketones, diabetic sick day rules, DKA
  17. diabetes and ketones, diabetic sick day rules, DKA
  18. diabetes and ketones, diabetic sick day rules, DKA
  19. diabetes and ketones, diabetic sick day rules, DKA
  20. Insulin pumps UK 2018
  21. Page 0021
  22. Insulin pumps UK 2018
  23. Insulin pumps UK 2018
  24. Insulin pumps UK 2018
  25. Medtronic Minimed 670G insulin pump
  26. Insulin pumps UK 2018
  27. Omnipod Insulet insulin pump with insulin pods
  28. Insulin pumps UK 2018
  29. Insulin pumps UK 2018
  30. Insulin pumps UK 2018
  31. Desang diabetes kitbags
  32. London Medical, London Diabetes Centre, private diabetes clinic
  33. London Medical, London Diabetes Centre, private diabetes clinic
  34. London Medical, London Diabetes Centre, private diabetes clinic
  35. London Medical, London Diabetes Centre, private diabetes clinic
  36. Making Carbs count: Counting carbs for the diabetic diet
  37. Making Carbs count: Counting carbs for the diabetic diet
  38. Accu-Chek Insight insulin pump
  39. Accu-Chek Insight insulin pump
  40. Free diabetes magazine, living with diabetes, the diabetic diet, carb counting

Related Issues

powered by PageTiger